Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu8F4 in Advanced Hematologic Malignancies
NCT02530034Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2019
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Hu8F4 in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS) and 2 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Minimum safety data at 4 weeks and Biologically-effective dose at 4 weeks. Started Jan 2019; status: terminated.
02
Drugs
Hu8F4
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)myelofibrosis (MF)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02530034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530034.